Advertisement

U.S. Markets closed

S&P Futures
5,962.25
+4.00(+0.07%)
Dow Futures
43,967.00
+66.00(+0.15%)
Nasdaq Futures
20,919.50
+25.50(+0.12%)
Russell 2000 Futures
2,405.50
-0.30(-0.01%)
Crude Oil
72.18
+0.49(+0.68%)
Gold
2,664.20
-12.10(-0.45%)

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

3.8400

-0.0900

(-2.29%)

At close: 04:00PM EST

3.9200

+0.08

(+2.08%)

After hours:

04:35PM EST

Trade prices are not sourced from all markets

All

PR Newswire
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Advancium Health Network ("Advancium"), a public charity founded by Deerfield Management and the Deerfield Foundation to meet the needs of underserved patient populations, today announced entry into an exclusive option agreement for the acquisition of ALRN-6924, a clin
PR Newswire
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the presentation of two abstracts detailing LTI-03's pre-clinical and Phase 1b (NCT05954988) results in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF).